Want to create an interactive transcript for this episode?
Podcast: PeerView Clinical Pharmacology CME/CNE/CPE Video
Episode: Prof. Dr. med. Stephan Stilgenbauer - New Rules for BTK Inhibitors in CLL: Benchmarks for Evidence-Based Treatment Selection, Sequencing, and Safety Management
Description: Go online to PeerView.com/DPX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The emergence and validation of the Bruton tyrosine kinase (BTK) inhibitor agent class in chronic lymphocytic leukemia (CLL) has informed the modern, more personalized approach to patient management—are you prepared to challenge your skills and see how the experts navigate this changed clinical landscape? Find out by viewing this Clinical Consults educational activity recorded at the annual European hematology meeting in Vienna; throughout experts will explore the evidence-based use of BTK inhibitors in these different CLL settings. Tu...